What changed for Epilepsy
A plain English summary of what recently moved in the public data Voxsanity tracks for Epilepsy. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials recruiting worldwide 313 to 314 (+1)
- Trials on record 2,013 to 2,021 (+8)
Newly subsidised on the PBS
No medicines were newly subsidised on the PBS for Epilepsy in July 2026. Voxsanity tracks 20 PBS-subsidised medicines for this condition; none of them was listed for the first time this month.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
The 30 most recent of 136 trials tracked for Epilepsy that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT03678753 · results posted 2 July 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT03678753) enrolled 169 people with a type of epilepsy that causes generalised tonic-clonic seizures (sometimes called "grand mal" seizures). Participants were randomly assigned to receive either cenobamate (85 people) or a placebo — a dummy treatment with no active ingredient (84 people). The trial was measuring changes in how often these seizures occurred during the treatment period compared to before the trial began. The reported data shows the following numbers. For participants in the USA and the rest of the world, th...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05163314 · results posted 9 June 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT05163314) enrolled 352 participants who received a drug called soticlestat as part of a long-term open-label extension study — meaning all participants knew they were receiving the treatment. The trial was tracking a range of safety-related measures over time, including any unwanted medical events that occurred after starting the drug, thoughts of self-harm or suicide (using a standardised questionnaire called the Columbia-Suicide Severity Rating Scale), changes in body weight and height, stages of puberty development in c...
-
NCT05301894 · results posted 13 February 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT05301894) enrolled 19 participants, all of whom received at least one dose of the study drug, NBI-827104. No participants were recorded as having completed the study, meaning all 19 did not finish — though the data does not explain why. The trial was focused on tracking serious unwanted health events (called "serious treatment-emergent adverse events") that either appeared or got worse after participants started taking the study drug. The reported data shows that the primary thing being measured was how many participants...
-
NCT05218655 · results posted 22 December 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05218655) enrolled 101 participants who all received at least one dose of a medicine called vatiquinone. The trial had one single group — meaning all participants received the same treatment, with no comparison group. The main thing the trial was set up to measure was how many participants experienced "treatment-emergent adverse events" (TEAEs) — that is, any unwanted medical occurrence that happened after taking the study drug and within 30 days of the last dose. The reported data shows that out of 101 participants, 91 e...
-
NCT04686786 · results posted 11 December 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04686786) enrolled 105 participants, all of whom received at least one dose of the study drug, CVL-865 at 25 mg. The trial was an open-label study — meaning all participants knew what they were taking — and it was primarily focused on tracking safety-related measurements, including unwanted medical events (called adverse events), heart rhythm readings, vital signs like blood pressure and heart rate, physical and neurological check-ups, and any signs of suicidal thoughts. Thirty-nine participants completed the study, while...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04519645 · results posted 3 October 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04519645) involved newborns experiencing seizures and compared two approaches: a medicine called lacosamide and an active comparator (an existing seizure medicine). A small number of participants also had a "no treatment" observation period, though this group did not continue into the main treatment phase. In total, around 26 newborns received treatment — approximately 14 in the lacosamide group and 12 in the active comparator group. The trial's main goal was to measure how much seizure activity (recorded in minutes of sei...
-
NCT04325282 · results posted 4 September 2025
According to the results reported on ClinicalTrials.gov, this trial involved 22 children diagnosed with a condition called SeLECTS (a type of childhood epilepsy). It used a "crossover" design, meaning each child received both a real version and a fake (sham) version of a brain stimulation treatment called repetitive transcranial magnetic stimulation (rTMS) — with a one-week rest period in between. The trial was measuring two things: the frequency of abnormal brain activity bursts seen on a brain wave recording (called interictal epileptiform discharges, or IEDs), and how connected different re...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03355209 · results posted 3 July 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03355209) enrolled 296 participants across two groups — Cohort A (the larger group, with around 87 people per arm) and Cohort B (a smaller group, with around 11 people per arm). The trial was testing a medicine called ZX008 (fenfluramine) at two different daily doses — 0.2 mg/kg/day and 0.8 mg/kg/day — compared to a placebo (a dummy treatment with no active ingredient), in people with Lennox-Gastaut syndrome, a type of epilepsy that causes "drop seizures" (seizures that make a person suddenly fall or drop). The trial had t...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05769634 · results posted 26 June 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05769634) enrolled 20 participants, all of whom completed the study with no drop-outs. The trial was looking at something called the "Heartbeat Evoked Potential" (HEP) — a tiny electrical signal measured in the brain that is timed to each heartbeat. Researchers believe this signal reflects how the brain picks up on signals from the heart. The study used an "Interoceptive Challenge Battery," which is a set of tasks designed to test how the brain and body sense internal physical states. The trial measured changes in this bra...
-
NCT04244175 · results posted 30 May 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04244175) enrolled 154 people in total across three groups: 51 received a placebo (a dummy treatment with no active ingredient), 51 received a lower dose of CVL-865 (7.5 mg taken twice daily), and 52 received a higher dose of CVL-865 (25 mg taken twice daily). The trial was measuring changes in the frequency of focal onset seizures — a type of seizure that starts in one part of the brain — during a treatment period compared to a baseline period recorded before treatment began. The reported data shows the main outcome was...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04391569 · results posted 29 May 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04391569) enrolled 100 people in total — 51 received a medicine called ganaxolone and 49 received a placebo (a dummy treatment with no active ingredient). The trial was looking at people experiencing status epilepticus, a serious condition where seizures do not stop on their own. The study measured whether ganaxolone could stop seizures within 30 minutes without needing extra seizure medicines, whether it prevented the need for strong anaesthetic drugs given through a drip, and what unwanted medical events occurred during...
-
NCT04912856 · results posted 14 February 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04912856) involved 8 children in total — 5 who had previously received the study drug XEN496 in an earlier trial, and 3 who had previously received a placebo (a dummy treatment with no active ingredient). The trial was measuring the safety and tolerability of XEN496 by tracking how many participants experienced adverse events (unexpected or unwanted health occurrences) and serious adverse events (more significant health occurrences) during the study period. The reported data shows that across both groups, all 8 participan...
-
NCT05288283 · results posted 3 February 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05288283) was studying a medicine called GWP42003-P (a cannabidiol-based treatment) compared to a placebo (an inactive dummy treatment) in people with a type of epilepsy called Epilepsy with Myoclonic-Atonic Seizures (EMAS), which causes several kinds of seizures including drop attacks. The trial had two parts: Part A aimed to measure whether seizure frequency changed over a 14-week treatment period, and Part B aimed to record any notable changes in participants' health checks, such as vital signs, physical examinations, h...
-
NCT03443388 · results posted 9 January 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03443388) tested a deployable helmet device designed to protect people with epilepsy from head injuries during seizures. The study ran in two parts. Part 1 involved 4 participants and tested whether the helmet deployed successfully during a staged (controlled) fall. Part 2 then involved a further 5 participants split across two groups — some wore the helmet first and then did not wear it, while others did the reverse — to see how the helmet performed during real-life seizures. In total, 9 people started the trial and 8 com...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04940624 · results posted 1 January 2025
According to the results reported on ClinicalTrials.gov, this trial looked at a medicine called soticlestat compared to a placebo (a dummy treatment with no active ingredient) in people with a serious form of epilepsy. A total of 144 people took part — 71 in the placebo group and 73 in the soticlestat group. The trial measured how often participants experienced convulsive seizures (seizures involving shaking or loss of muscle control) over the course of the study, and whether the number of those seizures changed compared to before the trial started. The reported data shows that, on average, t...
Read the full trial page · View reported results on ClinicalTrials.gov ↗
-
NCT04387435 · results posted 28 August 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04387435) enrolled only one participant in the intervention arm. The study was measuring two things: changes in seizure frequency or duration (the primary focus), and changes in heart rate and blood pressure during specific physical tests — such as tilting upright, deep breathing, a breathing-pressure exercise called the Valsalva manoeuvre, and a cold stimulus test (the secondary focus). The reported data shows that the single participant who started the trial did not complete it. Because of this, no measurement results w...
-
NCT04639310 · results posted 23 August 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04639310) enrolled a small number of children with a rare genetic epilepsy condition called KCNQ2-DEE. Eight participants took part in total — five received the investigational medicine XEN496 and three received a placebo (a dummy treatment with no active ingredient). The trial was measuring changes in how often children experienced certain types of seizures, using diaries kept by parents and caregivers over a treatment period of roughly 15 weeks. The reported data shows that, for the main thing being measured — the perce...
-
NCT04938427 · results posted 21 August 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04938427) enrolled 270 people in total — 136 in the placebo group and 134 in the soticlestat group. The trial was studying a medicine called soticlestat in people who experience "major motor drop" seizures (a type of seizure where the body suddenly loses muscle control and the person drops). The main thing being measured was whether the number of these seizures per 28 days changed from the start of the trial to during treatment. The reported data shows that, when looking at the full treatment period, the placebo group had...
Read the full trial page · View reported results on ClinicalTrials.gov ↗
-
NCT05201703 · results posted 31 July 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled a very small number of participants — just 4 people in total. They were split into two groups: one person received a daily dose of 4 mg of Fycompa (a seizure medication), and three people received 4 mg daily with the option to increase to 6 mg daily. The trial was measuring what is called a "responder rate" — that is, how many participants experienced at least a 50% reduction in the number of seizures they had, compared to before the study started. The reported data shows that by the end of the study, only 2 of the 4...
-
NCT02535091 · results posted 14 May 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 1,340 people in total across three groups: 83 people taking YKP3089 (now known as cenobamate) alongside a medicine called phenytoin, 37 people taking it alongside phenobarbital, and 1,220 people taking it alongside other epilepsy medicines. The trial was primarily measuring how many participants experienced side effects (called treatment-emergent adverse events) during the study. Relatively few participants completed the study — 22, 5, and 236 people in each group respectively — while the majority did not finish. The...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03785028 · results posted 1 May 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03785028) enrolled 5 participants, all in a single experimental group, and all 5 completed the study. The trial was measuring brain activity patterns in people who had electrodes placed on or in their brains (a method called electrocorticography, typically used in certain medical procedures). Researchers were looking at how the brain holds and prioritises different types of memories — such as faces, scenes, and words — during a short-term memory task, and how brain signal patterns change depending on which memory item is c...
-
NCT02408549 · results posted 14 December 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT02408549) enrolled 239 participants, all of whom received the medication lacosamide. Of those, 157 completed the study and 82 did not. The trial was a long-term follow-on study that focused on monitoring unwanted events (called adverse events) that occurred during treatment, as well as tracking whether participants developed any new types of seizures — specifically absence seizures (brief "blank staring" episodes) or myoclonic seizures (sudden brief muscle jerks) — that they had not experienced before starting the medicati...
-
NCT05089682 · results posted 1 November 2023
According to the results reported on ClinicalTrials.gov, this trial looked at a Deep Brain Stimulation (DBS) system — a device implanted in the brain that delivers electrical signals — and how it related to sleep. Four people started the trial, two completed all scheduled activities, and two did not finish. Because this was a very small study, the numbers below describe the group's results overall rather than a large population. The reported data shows several sleep-related measurements taken across what appear to be different time points (though the trial did not label these time points by n...
-
NCT02823145 · results posted 25 September 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT02823145) was an open-label extension study involving 374 participants who received ZX008 (fenfluramine), a medication being studied for convulsive seizures. One additional participant was enrolled but did not receive treatment. The trial tracked what happened to participants over a long-term treatment period of up to 42 months, measuring both how often unwanted medical events occurred and how frequently participants experienced convulsive seizures (episodes involving shaking or jerking movements). The reported data shows...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02914314 · results posted 15 September 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT02914314) looked at the drug perampanel in very young children with epilepsy, aged from 1 month up to 4 years old. A total of 21 children took part, divided into four age groups: 4 children aged 1 to 6 months, 5 children aged 6 to 12 months, 9 children aged 12 to 24 months, and 3 children aged 24 to 48 months. The trial ran in two parts — a core phase of up to 20 weeks, followed by an extension phase of up to a further 36 weeks. Because no primary outcome measure data was submitted to ClinicalTrials.gov for this trial, onl...
-
NCT03154307 · results posted 23 June 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT03154307) was designed to look at the effects of repetitive transcranial magnetic stimulation (rTMS — a non-invasive brain stimulation technique) on epilepsy-related measures in people with seizures. The study had four planned groups: weekly rTMS, monthly rTMS, a sham (inactive/pretend) rTMS group, and a short-term protocol group. However, the reported data shows that only 2 participants were enrolled, both in the weekly rTMS group, and only 1 of those 2 completed the study. No participants were enrolled in any of the othe...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00441896 · results posted 2 June 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT00441896) enrolled 57 infants and young children in total across five groups (called cohorts). Each cohort tested different doses or dosing schedules of an intravenous drug called ganaxolone compared to a placebo (an inactive substance). Participants were assigned to one of two sequences — either receiving ganaxolone first or placebo first — and then switched over the course of the study. The main thing being measured was how the number of "spasm clusters" (episodes of repeated muscle jerks) per day changed from the starti...
-
NCT02519439 · results posted 14 February 2023
According to the results reported on ClinicalTrials.gov, this trial enrolled 26 people, all of whom received a medicine called ganaxolone. The trial was an open-label extension study, meaning all participants knew they were taking the medicine, and it followed on from an earlier trial. The main thing being measured was how much the frequency of seizures changed over time compared to where each person started (their "baseline"). Of the 26 people who started, only 5 completed the study, and 21 did not complete it. The reported data shows that, on average, participants experienced a 41.86% reduc...
-
NCT01963208 · results posted 14 February 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT01963208) looked at a medicine called ganaxolone compared to a placebo (a dummy treatment with no active ingredient) in people with epilepsy who experience ongoing seizures. The main group of interest (called Cohort 2) started with 179 people taking ganaxolone and 180 taking placebo during the first, blinded phase — meaning neither the participants nor the doctors knew who was getting which treatment. A smaller group (Cohort 1) included 24 on ganaxolone and 22 on placebo. The trial also included a later open-label phase (w...
-
NCT03350035 · results posted 15 December 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT03350035) looked at a drug called GNX given at three different dose levels — low, medium, and high — to people experiencing a serious type of prolonged seizure called Status Epilepticus (SE). A total of 17 people started the trial (5 in the low-dose group, 4 in the medium-dose group, and 8 in the high-dose group), and 14 completed it (3, 4, and 7 respectively). The trial was primarily measuring how many participants did not need to be given a stronger, intravenous (directly into the vein) anaesthetic drug to stop their sei...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
See all 136 reported results for Epilepsy
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, epilepsy currently attracts a very large amount of public research investment from the United States government, which signals that this condition is treated as a serious scientific priority at the global level. However, the direction of that funding has been falling year on year, which is worth noting for patients. A declining trend does not mean research is stoppin...
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.